Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VCYT vs CDNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CDNA Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

CDNA Overall Winner 6-Pillar Tally: VCYT 3 – 3 CDNA Matrix Metrics: VCYT 4 – 6 CDNA

As of Nov 16, 2026, CareDx, Inc. (CDNA) is the stronger overall head-to-head candidate over Veracyte, Inc. (VCYT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Options & Positioning, R&D & Supply-Chain Moat). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas CDNA carries 24.5/100 (STRONG SELL) at $73.72 (47.1x Forward P/E, 1.6% operating margin).

  • Composite vs. Pillar Nuance: While VCYT currently prints a higher short-term Unified Composite Score (49.1/100 HOLD vs. CDNA 24.5/100 STRONG SELL), CDNA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (1.6% vs. 15.0% operating margin) and revenue trajectory (+39.3% vs. +15.1% YoY).
  • Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile CDNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VCYT vs CDNA
VCYT NASDAQ
Veracyte, Inc.
Services-Medical Laboratories
$24.01
-1.32% 1D
Market Cap $2.0B
TTM Revenue $582M
Forward P/E 15.3x
Beta / 30D Vol 3.01β · 199% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 57.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.8%), weak momentum, RSI 28
RSI-14: 27.8 · SMA20: $39.20 · SMA50: $41.79
CDNA NASDAQ Head-to-Head Winner
CareDx, Inc.
Services-Medical Laboratories
$73.72
-5.34% 1D
Market Cap $4.1B
TTM Revenue $497M
Forward P/E 47.1x
Beta / 30D Vol 1.21β · 98% Vol
Unified Composite Score
24.5 / 100 STRONG SELL
Tech 15.0 Fund 36.0 Flow 70.0 Mom 25.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.0 · SMA20: $77.09 · SMA50: $66.80

6-Pillar Scorecard Institutional Category Breakdown (VCYT 3 – 3 CDNA)

Columns: Metric · VCYT · CDNA
1. Valuation Multiples VCYT
Forward P/E 15.3x 47.1x
Trailing P/E 15.8x 32.9x
PEG Ratio N/M N/M
EV / Revenue 3.1x 7.8x
2. Growth & Scale CDNA
Revenue Growth (YoY) +15.1% +39.3%
Earnings Growth (YoY) +58.3% N/A
TTM Revenue (USD) $582M $497M
Market Cap $2.0B $4.1B
3. Profitability & Quality VCYT
Gross Margin 74.2% 71.0%
Operating Margin 15.0% 1.6%
Net Profit Margin 21.8% 25.9%
Return on Equity (ROE) 9.4% 33.0%
4. Balance Sheet & Cash Flow VCYT
Cash Generation (TTM) $162M $60M
Cash Flow Margin 27.8% 12.0%
Net Cash / Leverage $159M Net Cash $221M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CDNA
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 197.3% (47th %ile) 56.8% (18th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) 1.04x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CDNA
OpEx & R&D Intensity 59.2% of Rev ($344M) 69.4% of Rev ($345M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VCYT (4) vs CDNA (6)
Institutional Metric VCYT CDNA Criterion Row Edge
Market Capitalization
Scale
$2.0B $4.1B Larger Scale CDNA
Trailing P/E Ratio
Valuation
15.8x 32.9x Lower Multiple VCYT
Forward P/E Ratio
Valuation
15.3x 47.1x Lower Multiple VCYT
Revenue Growth (YoY)
Growth
+15.1% +39.3% Higher Growth CDNA
Operating Margin (TTM)
Profitability
15.0% 1.6% Higher Margin VCYT
Net Profit Margin
Profitability
21.8% 25.9% Higher Margin CDNA
Return on Equity (ROE)
Capital Efficiency
9.4% 33.0% Higher ROE CDNA
52-Week Range Position
Momentum
5% ($22–$61) 77% ($15–$91) Stronger Trend CDNA
Beta / 30D Volatility
Risk Regime
3.01β · 199% Vol 1.21β · 98% Vol Lower Realized Risk CDNA
Unified Institutional Score
Composite Signal
49.1 / 100 (HOLD) 24.5 / 100 (STRONG SELL) Higher Composite VCYT
Trailing 12M Revenue (USD)
Operating Scale
$582M $497M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.2% 71.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.1x EV/Rev N/M PEG · 7.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$162M ($159M Net Cash) $60M ($221M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDNA +59.51 pp
VCYT: -44.32% · CDNA: +15.19%
3M Horizon CDNA +100.62 pp
VCYT: -40.98% · CDNA: +59.64%
6M Horizon CDNA +300.18 pp
VCYT: -42.14% · CDNA: +258.04%
1Y Horizon CDNA +404.3 pp
VCYT: -39.78% · CDNA: +364.52%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VCYT Revenue CDNA Revenue VCYT Op. Margin CDNA Op. Margin Margin Leader
FY2018 $90M $80M -24.2% -20.3% CDNA
FY2019 $120M $130M -12.6% -19.3% VCYT
FY2020 $120M $190M -30.1% -11.7% CDNA
FY2021 $220M $300M -37.3% -10.0% CDNA
FY2022 $300M $320M -13.9% -24.0% VCYT
FY2023 $360M $280M -23.8% -72.5% VCYT
FY2024 $450M $330M 3.6% 12.2% CDNA
FY2025 $520M $380M 11.2% -8.1% VCYT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VCYT BREAKDOWN
99d in phase · OBV DISTRIBUTION
Current IV 197.3%
IV Percentile 47th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CDNA CONSOLIDATION
30d in phase · OBV NEUTRAL
Current IV 56.8%
IV Percentile 18th %ile
Put/Call OI Skew 1.04x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VCYT Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.0B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment 59.2% of Rev ($344M)
90D Engineering Disclosures 0 Published
CDNA Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $4.1B market capitalization and 1.6% operating margin.
OpEx & R&D Reinvestment 69.4% of Rev ($345M)
90D Engineering Disclosures 0 Published

Investor FAQ VCYT vs CDNA Key Questions & Quantitative Answers

As of Nov 16, 2026, CareDx, Inc. (CDNA) is the stronger overall head-to-head candidate over Veracyte, Inc. (VCYT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Options & Positioning, R&D & Supply-Chain Moat). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas CDNA carries 24.5/100 (STRONG SELL) at $73.72 (47.1x Forward P/E, 1.6% operating margin). Composite vs. Pillar Nuance: While VCYT currently prints a higher short-term Unified Composite Score (49.1/100 HOLD vs. CDNA 24.5/100 STRONG SELL), CDNA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (1.6% vs. 15.0% operating margin) and revenue trajectory (+39.3% vs. +15.1% YoY). Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile CDNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CDNA leads the Growth & Scale pillar: VCYT posts +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin), compared with CDNA at +39.3% YoY revenue growth and N/A YoY earnings growth on $497M TTM revenue (71.0% gross margin, 1.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VCYT cumulative revenue shifted +477.8% while CDNA shifted +375.0%. In operating R&D and SG&A reinvestment, VCYT deploys 59.2% of Rev ($344M) (0 90-day corporate R&D disclosures) versus 69.4% of Rev ($345M) (0 disclosures) for CDNA.

VCYT screens cheaper on headline valuation multiples. VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin), whereas CDNA trades at 47.1x Forward P/E, 32.9x Trailing P/E, N/M PEG, and 7.8x EV/Revenue (12.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VCYT (9.4% ROE) versus CDNA (33.0% ROE) capital efficiency.

In options market volatility and institutional positioning, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk). By comparison, CDNA carries 56.8% implied volatility (18th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.21β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.